1)Pancreatic cancer: Important role of moderate whole-body hyperthermia in combination with palliative chemotherapy
Hohneck et al. published in 'Cancers' a retrospective analysis of 206 pancreatic cancer patients who were treated with palliative chemotherapy at the Öschelbronn Clinic from 2015-2019:
64 patients did not receive chemotherapy due to poor general condition or individual patient decision. Palliative chemotherapy was performed as standard in 142 patients (69%) with good general health. In addition to chemotherapy, 117 patients (82%) received mistletoe therapy and 74 patients (52%) received hyperthermia. The median survival of patients with chemotherapy alone was 8.6 months, with chemotherapy and mistletoe therapy 11.2 months, and with chemotherapy, mistletoe therapy and hyperthermia 18.9 months. Moderate whole-body hyperthermia with 5 Heckel devices played the most important role in addition to the use of 1 locoregional hyperthermia device. These encouraging results justify the use of moderate GHT in pancreatic cancer and motivate prospective studies.
2)Fifth Swiss radiotherapy with thermography-controlled wIRA surface hyperthermia
After the Lindenhofspital Bern and the cantonal hospitals of Aarau, Winterthur and Lucerne, the Center for Integrative Oncology (ZIO) in Zurich, in collaboration with Radiotherapie Hirslanden in Männedorf, established the fifth Swiss radiotherapy center that offers thermography-controlled wIRA surface hyperthermia with hydrosun®TWH1500 offers. The TWH users all cooperate in the “Swiss Hyperthermia Network”, which also regulates reimbursement of costs. In addition to the treatment of inoperable, previously irradiated chest wall recurrences, its use in large skin tumors and superficial metastases from various primary tumors is playing an increasing role. A clinical study is being prepared for squamous cell and basal cell carcinoma.
3) Invasive temperature measurements: Thermography-controlled wIRA surface hyperthermia meets ESHO quality requirements
Piazena et al published in Int J Hyperthermia invasive temperature measurements in healthy subjects who were treated with thermography-controlled wIRA surface hyperthermia with hydrosun®TWH1500:
With hydrosun®TWH1500, the maximum temperature is limited to 43°C by automatic thermographic control in order to reduce the risk of burns to a minimum (incidence in clinical use to date < 1 per mille). Temperatures up to 41°C were measured at a depth of 10mm and up to 40°C at a depth of 20mm. Warm-up times, temperature rises, SAR (Specific Absorption Rate) and other parameters are described in detail. The measurements showed that hydrosun®TWH1500 complies with all ESHO quality criteria for surface hyperthermia.
※본 게시물은 독일 heckel gmbH.에서 발행한 뉴스레터를 전달받아 발행한 것입니다.
